Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
about
Probing a protein-protein interaction by in vitro evolutionThe future of biologic agents in the treatment of Sjögren's syndromeThe current status of targeting BAFF/BLyS for autoimmune diseasesB-cell survival factors in autoimmune rheumatic disordersBelimumab in systemic lupus erythematosus: a perspective reviewCellular targeting in autoimmunityDrugs derived from phage display: from candidate identification to clinical practiceA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusA therapeutic role for BLyS antagonistsBAFF and rheumatic autoimmune disorders: implications for disease management and therapyA soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeysFirst Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism.Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases.Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and futureVNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicryBelimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada StudyEfficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.Beyond natural antibodies: the power of in vitro display technologies.Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFFBAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Detection of biomarkers using recombinant antibodies coupled to nanostructured platformsEfficacy and safety data of belimumab in patients with systemic lupus erythematosus.Tailored amino acid diversity for the evolution of antibody affinityMiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts.Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.Generation and analysis of the improved human HAL9/10 antibody phage display libraries.Advances in phage display technology for drug discovery.Cytokine disturbances in systemic lupus erythematosus.BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosusThe discovery and development of belimumab: the anti-BLyS-lupus connectionBAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe diseaseTargeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders.Prospects for B-cell-targeted therapy in autoimmune disease.Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosusChallenges in bringing the bench to bedside in drug development for SLE.Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.Applications of ribosome display to antibody drug discovery.
P2860
Q24546265-BC95F1A4-078A-41BE-9A58-C96D3F353530Q24681044-CAF91484-DD6C-4CF4-90E7-77C889FD7952Q24796930-95F63271-CA43-41F9-8976-1C19B7B185F2Q26796484-CF554D4F-DA10-4F92-B778-2DEE0BEE9DE6Q26796486-C72E47B1-B4A5-4D32-B8CC-81C80F5F34EAQ26824580-6FC8F65B-9B5D-49E0-AFAB-C00D29E315F8Q27007101-20081323-5B27-4AA1-9F6F-48DF57E10F03Q28254310-32BAF62B-2FED-41F3-99F6-DA7E8B030244Q28269809-96D86383-FD7C-4DDD-839E-E99AB6D9E164Q28292058-6FF730E1-BEB0-4769-A145-632DDD5BB15AQ28293722-44AAE645-04E4-4B16-8319-FFFAFE7A3795Q30490276-73932FA9-6862-4148-AA61-025A71C3A614Q33584291-D734F41D-0A34-4696-96A5-5399DF8DB310Q33586280-C489EA52-870B-4A2B-BC80-1B785F2F1C3EQ33601679-666408D2-1F1A-4035-8C0B-EFC69C12B1F8Q33688370-DAF74235-477B-4EAC-BA0B-E35708342596Q33695128-B165D98C-BE55-466A-869B-9E89F23D7462Q33698040-9A9E55B1-4C56-4C04-8879-693C7949DEEEQ33803763-2FBCEB27-BB67-43FA-A40F-55F35D953439Q33841864-8A955BE9-BF57-4C0B-8360-8C3D6504D8FBQ33960050-BE846A00-2131-4C33-A90E-D6C431795C48Q34245983-07516358-43EB-4559-92CC-4FCB593FA782Q34352221-82465E39-A88F-4204-BA2C-F3109B7B0A96Q34369628-637A2EEA-BEBB-4B9D-AE0C-AF3219FB0817Q34394742-81D91C43-FE84-4EE8-B510-082F19F49909Q34434727-5A350CD1-0BC3-4AD4-A1FA-952836BF0A3FQ34960458-608A33CE-E9CB-4D6A-928A-9ED3DDFAF3AFQ35008162-C7BEC168-B19F-43F7-B2CC-688342396613Q35608279-AC6B8E31-3ADA-43E5-A96B-CE445E581E2BQ35614190-85937B32-C9B6-47AD-B33D-1A899A5AD20AQ35617573-BEDFB380-C943-4EFA-BDA1-5B3C22777788Q35686772-365B990D-EE18-401A-8FF4-D7C02560F509Q35691272-53894907-E07D-4AE9-8015-3850A7D7F6D3Q35732635-A9FEFBEF-2C3B-450E-994D-5015447F25F4Q35782879-ADF82103-6310-4F69-9C1D-75AF40A520ECQ35930307-F0823D56-9037-4B4B-8DF4-4303357564DDQ35954719-57A1B9D2-B154-4E34-9E1F-6552C21420B8Q35968394-1BED23CF-68E2-46A0-89D0-4D0535F677CEQ35986113-8665B1D9-E29C-4845-BC78-EBC9A62DB75AQ36040839-3413B2A5-80BB-43CD-915C-376AB3F790AF
P2860
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Generation and characterizatio ...... ies of B lymphocyte stimulator
@ast
Generation and characterizatio ...... ies of B lymphocyte stimulator
@en
Generation and characterizatio ...... ies of B lymphocyte stimulator
@nl
type
label
Generation and characterizatio ...... ies of B lymphocyte stimulator
@ast
Generation and characterizatio ...... ies of B lymphocyte stimulator
@en
Generation and characterizatio ...... ies of B lymphocyte stimulator
@nl
prefLabel
Generation and characterizatio ...... ies of B lymphocyte stimulator
@ast
Generation and characterizatio ...... ies of B lymphocyte stimulator
@en
Generation and characterizatio ...... ies of B lymphocyte stimulator
@nl
P2093
P3181
P356
P1476
Generation and characterizatio ...... ies of B lymphocyte stimulator
@en
P2093
Bonnie Sturm
Bryan M Edwards
Carol Poortman
Claire L Dobson
David M Hilbert
Donara Abramian
Elizabeth Williams
Gil H Choi
Kevin P Baker
P304
P3181
P356
10.1002/ART.11299
P407
P577
2003-11-01T00:00:00Z